A team at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has unveiled a new strategy that dramatically enhances the precision and safety of CRISPR-Cas9 editing in human blood stem cells. Called the 'SMArT' platform, it aims to overcome a major barrier limiting broader clinical use of genome-editing therapies.
The work targets hematopoietic stem cells, the source of all blood and immune cells, where off-target edits have posed significant risks. By making edits more accurate, the approach could reduce the chance of unintended mutations that might lead to cancer or other complications.
Details on the platform's specific mechanism remain limited from available reports, but the breakthrough is described as addressing one of the field's core challenges. Naldini's group has a track record of advancing gene therapy toward clinical trials.
If validated in further studies, SMArT could accelerate new treatments for genetic blood disorders such as sickle cell disease and beta-thalassemia. It may also expand CRISPR applications into other tissues requiring high editing fidelity.